The exploration of the MACC1/HGF/c-MET pathway in colon cancer provides favorable evidence for drug targeting of MACC1 and regulation of MACC1/HGF/c-MET in colon cancer therapy. The gene discussed is MET; the disease is colonic neoplasm.